Literature DB >> 15664884

Mechanism of vasoselective action of mebudipine, a new calcium channel blocker.

Hossein Mirkhani1, Mehrdad Dirin, Iris Youssef-Zayeh.   

Abstract

In previous studies, mebudipine, a newly synthesized dihydropyridine calcium channel blocker, showed a considerable vasoselective action. To investigate the mechanism of this property, the pattern of inhibitory action on the KCl-induced contraction in isolated rat aortic rings and the effect of changing resting membrane potential on the potency of this compound were considered. In addition, its chronotropic and inotropic actions were also studied. Mebudipine inhibited KCl-induced contractions. Its inhibitory effect was progressive and needed time to reach maximum. Incubation of the aortic rings in depolarizing physiological solution (high potassium, zero calcium) resulted in the augmentation of mebudipine effect. The potency of mebudipine in inhibiting aortic contractions and its time- and voltage-dependent action were significantly greater than those of nifedipine. In comparison with nifedipine, mebudipine showed a greater negative chronotropic effect, but in the case of negative inotropism, the reverse relation was observed. It is concluded that mebudipine has a greater time- and voltage-dependent inhibitory effect, as compared to nifedipine and this property could explain its prominent vasoselective action. It has also marked negative chronotropic effect and minor negative inotropic action. With regard to the above findings, mebudipine might have a selective and protective calcium channel blocking effect in ischemic regions (ischemia-selectivity), and the potential to be used in cardiovascular diseases without causing harmful effects such as reflex tachycardia and heart failure which have sometimes been seen with the older agents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15664884     DOI: 10.1016/j.vph.2004.12.002

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  5 in total

1.  Effect of mebudipine on oxidative stress and lipid peroxidation in myocardial ischemic-reperfusion injury in male rat.

Authors:  Rafigheh Ghyasi; Gholamreza Sepehri; Mustafa Mohammadi; Reza Badalzadeh; Akbar Ghyasi
Journal:  J Res Med Sci       Date:  2012-12       Impact factor: 1.852

2.  The effect of mebudipine on cardiac function and activity of the myocardial nitric oxide system in ischaemia-reperfusion injury in rats.

Authors:  R Ghyasi; M Mohammadi; R Badalzadeh; B Rashidi; G Sepehri
Journal:  Cardiovasc J Afr       Date:  2011 Nov-Dec       Impact factor: 1.167

3.  Cardioprotective Effects of Mebudipine in a Rat Model of Doxorubicin-Induced Heart Failure.

Authors:  Ehsan Aali; Habib Ghaznavi; Mohammad Soleiman Soltanpour; Massoud Mahmoudian; Massoumeh Shafiei
Journal:  Iran J Med Sci       Date:  2021-03

4.  Determination of Mebudipine in Human Plasma by Liquid Chromatography-tandem Mass Spectrometry.

Authors:  Arezoo Asgari; Farzad Kobarfard; Fariborz Keyhanfar; Shohreh Mohebbi; Maryam Noubarani
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

5.  Evaluation of mutagenicity of mebudipine, a new calcium channel blocker.

Authors:  Saeid Gholami; Fatemeh Soleimani; Farshad Hoseini Shirazi; Maryam Touhidpour; Massoud Mahmoudian
Journal:  Iran J Pharm Res       Date:  2010       Impact factor: 1.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.